managing high cost medications...timeline of therapeutic aerosols 1950 1980 2018 1962, medihaler duo...
TRANSCRIPT
![Page 1: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/1.jpg)
Managing High Cost
Medications
Presented By Joseph Pinto, R.Ph, M.S., MHA
Senior Director of Clinical Operations at Mount Sinai Downtown
Immediate Past President of the NYS Council of Health-System Pharmacists
and Past President of the NYC Society of Health-System Pharmacists
1
![Page 2: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/2.jpg)
Key Objectives
1. Discuss the impact that High Cost Medications
have on the hospitals/health systems ability to
manage costs
2. Describe methods for managing high cost
medications
3. Understand the use of data in managing costs
4. Explore the benefits of medication utilization
management initiatives
2
![Page 3: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/3.jpg)
RISING DRUG COSTS AND
HOSPITALS/HEALTH SYSTEMS
3
![Page 4: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/4.jpg)
Inpatient Drug Spending Trends
Source: AHA-FAH Drug Survey; 2012-14
AHA Annual Survey 4
The price of drugs (not utilization) is a major contributor to increased spending
Spending impacts patient access to care
![Page 5: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/5.jpg)
Contributing Factors to High Drug Costs
1. Drug ownership
2. Shortages
3. Drug delivery
methods
4. Cost-related
medication
nonadherence
5
![Page 6: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/6.jpg)
Drug Ownership
Navigate competitive generic manufacturers
Many companies correlate higher prices with
better quality drugs
6
![Page 7: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/7.jpg)
Drug Shortages
Anticipate changes
Identify hyperinflation early via market surveillance
Consider group purchasing
Have an action plan for supply dilemmas7
![Page 8: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/8.jpg)
Drug Delivery Methods
Device changes due to medical discoveries
Source Stein and Thiel, J Aerosol MPDD 8
Timeline of Therapeutic Aerosols
1950 1980 2018
1962, Medihaler Duo
– first combination
MDI therapy with
CFCs
1970, Autohaler –
rugged pocket size
device is made
1968, CFC Albuterol is
delivered by MDI and
DPIs
2000, Suspension
of Albuterol via
Ventolin HFA
1956, Inhaled
epinephrine via
DPI nebulizer
1987, Montreal Protocol signed
eliminating CFCs in MDIs
1990, Move
from using
CFCs to HFAs 2011, Last
CFC MDI is
phased out
of U.S.
Market
2005, Soft
mist inhaler -
Respimat
Inhalation
spray
introduced
![Page 9: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/9.jpg)
Patient Non-Adherence to Drug Therapy
9
![Page 10: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/10.jpg)
METHODS FOR MANAGING
HIGH COST MEDICATIONS
10
![Page 11: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/11.jpg)
The Role of Pharmacy Leadership
1. Review and update operational procedures
2. Maintain an open line of communication
3. Optimize collaboration among various disciplines
11
![Page 12: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/12.jpg)
Responsibilities of Pharmacy Leadership
12
Develop quantifiable measures and
deliverables
Strive to prioritize value-based
contracting with drug manufacturers
Minimize waste and go LEAN
Remain aware of current laws and
regulations
◦ USP Compliance
◦ Drug pricing programs such as 340B
![Page 13: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/13.jpg)
Effective Communication Strategies
13
Consider utilizing a pharmacy bulletin or
electronic correspondence to
communicate
Provide support to front line clinical
pharmacy staff
◦ Serve as a resource
◦ Encourage attendance of continuing education
and trainings
Walk-the-talk: position your team to
succeed
![Page 14: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/14.jpg)
Planning the Flow of Success
14
Set Quarterly Goals
Plan and Prepare
Weekly Objectives
Share Progress
Provide Feedback
Disseminate Regular Reports and Updates
1
2
3
4
5
Quarterly Weekly Daily As Needed
Adopted from www.weekdone.com
![Page 15: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/15.jpg)
Utilize PPP Reporting
15
Progress
Plans Problems
Adopted from www.weekdone.com
Progress. Highlight team accomplishments and tasks that have been completed successfully
Plans. Identify goals and objectives that must be prioritized
Problems. Brainstorm solutions to challenges in real-time
![Page 16: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/16.jpg)
“When it comes to working
toward a more collaborative
system, it’s all about the
alignment of incentives.
We need to demonstrate
efficacy and then give the
physicians a reason to care
about prescribing the most
cost-effective treatment.”
16
Doug Chaet
Chief Managed Care Officer, Sentara
Healthcare and Chairman, American
Association of Integrated Healthcare
Delivery Systems
![Page 17: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/17.jpg)
USING DATA TO MANAGE
HIGH COST DRUGS
17
![Page 18: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/18.jpg)
Capture Quality Metrics
Practice effective Monitoring and
Evaluation (M&E)
Consider the use of pharmacy
analytics software
◦ Discharge counseling and follow-up
Embrace pharmacy’s role in
population health with PHM
analytics
◦ Work to reduce avoidable
readmissions
18
REPORT
LEARN
SHARE
ACT
REVIEW
Adopted from blog.pharmapodhq.com
![Page 19: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/19.jpg)
Monitoring & Evaluation (M&E)
19
Set and track SMART performance
goals◦ Specific (S): clear performance target established
◦ Measureable (M): team can view progress in real-time
◦ Appropriate (A): target is in line with scope of work
◦ Realistic (R): target is tangible and achievable
◦ Time-bound (T): specific time frame is outlined and
understood
Adopted from Management Sciences for Health
![Page 20: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/20.jpg)
Pharmacy Analytics Software
20
![Page 21: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/21.jpg)
DRUG UTILIZATION
MANAGEMENT INITIATIVES
AND COST
21
![Page 22: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/22.jpg)
Moving Towards New Models of Care
Population health impact on volume distribution
Growing demand due to the aging population
Increased prevalence of chronic diseases
Shift of care must not impede patient care
22Source: HSG Advisors
![Page 23: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/23.jpg)
Multi-Disciplinary Collaboration
Active involvement of all staff to implement medication utilization management initiatives
◦ CPOE, MTM
and CDTM
23
Physician and clinical pharmacy relationship
◦ Rounds, renal dose adjustment and pharmacokinetic monitoring
Work as a unit to identify cost-effective treatments
![Page 24: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/24.jpg)
Pharmacy and Therapeutics Committee
Select various thought leaders and clinical experts
◦ Pharmacy leadership
◦ Medical chiefs
◦ Physician specialists
Establish core guidelines and protocols
◦ Seek to enhance patient safety and increase
standardization
Evaluate clinical evidence and project financial
impact of new/current medications
Consider alternative options for Formulary List
24
![Page 25: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/25.jpg)
Timeline of Approval
25Source: R Durvasula et al.
![Page 26: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/26.jpg)
Formulary Management
26
Various
strategies
P&T can
mandate
![Page 27: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/27.jpg)
Key Takeaways
27
#1: Prioritize collaboration
#2: Avoid compromising
patient safety and quality of
care
![Page 28: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/28.jpg)
Source: Managed Healthcare Executive 28
![Page 29: Managing High Cost Medications...Timeline of Therapeutic Aerosols 1950 1980 2018 1962, Medihaler Duo –first combination MDI therapy with CFCs 1970, Autohaler – rugged pocket size](https://reader033.vdocuments.us/reader033/viewer/2022050310/5f71c03d2d2240658d456383/html5/thumbnails/29.jpg)
References American Society of Health-System Pharmacists. ASHP guidelines on medication
cost management strategies for hospitals and health systems. Am J Health-Sys Pharm.
2008; 65:1368-84.
Briesacher et al. Patients At-Risk for Cost-Related Medication Nonadherence: A
Review of the Literature. JGIM. 180: 864-871.
Durvasula R et al. Standardized Review and Approval Process for High-Cost
Medication Use Promotes Value-Based Care in a Large Academic Medical System.
American Health & Drug Benefits. 2018; 11(2):65-73.
Flannery AH et al. Managing the Rising Costs and High Drug Expenditures in Critical
Care Pharmacy Practice. Pharmacotherapy. 2017; 37(1): 54-64.
Management Sciences for Health. Information Management: Monitoring and
Evaluation. 2012; 48.11.
NORC at the University of Chicago. Final Report: Trends in Hospital Inpatient Drug
Costs: Issues and Challenges. 2016; 10-11.
Stein SW, Thiel CG. The History of Therapeutic Aerosols: A Chronological
Review. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2017;30(1):20-41.
Weekdone: Weekly Planning + Quarterly Objectives
29